Migdal Insurance & Financial Holdings Ltd. increased its holdings in shares of Urogen Pharma (NASDAQ:URGN - Free Report) by 14.6% in the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 786,472 shares of the company's stock after purchasing an additional 100,000 shares during the quarter. Migdal Insurance & Financial Holdings Ltd. owned 1.71% of Urogen Pharma worth $8,698,000 as of its most recent filing with the SEC.
A number of other institutional investors and hedge funds have also recently bought and sold shares of URGN. CWM LLC grew its position in Urogen Pharma by 6,047.1% in the first quarter. CWM LLC now owns 5,225 shares of the company's stock valued at $58,000 after acquiring an additional 5,140 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new position in Urogen Pharma in the 4th quarter worth about $59,000. Lazard Asset Management LLC purchased a new position in Urogen Pharma during the 4th quarter valued at about $67,000. GAMMA Investing LLC grew its stake in Urogen Pharma by 6,908.4% during the 1st quarter. GAMMA Investing LLC now owns 7,499 shares of the company's stock valued at $83,000 after acquiring an additional 7,392 shares in the last quarter. Finally, Aquatic Capital Management LLC acquired a new stake in shares of Urogen Pharma during the 4th quarter valued at about $101,000. Institutional investors and hedge funds own 91.29% of the company's stock.
Wall Street Analysts Forecast Growth
A number of research firms have recently issued reports on URGN. Oppenheimer set a $31.00 price objective on Urogen Pharma and gave the company a "buy" rating in a research report on Friday, June 13th. The Goldman Sachs Group set a $16.00 price objective on Urogen Pharma and gave the company a "neutral" rating in a research report on Friday, June 13th. Scotiabank reaffirmed an "outperform" rating on shares of Urogen Pharma in a report on Friday, June 13th. HC Wainwright restated a "buy" rating and set a $50.00 price objective on shares of Urogen Pharma in a research report on Tuesday, July 8th. Finally, Guggenheim restated a "buy" rating and set a $30.00 target price (up previously from $15.00) on shares of Urogen Pharma in a research report on Friday, June 13th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus target price of $32.86.
Get Our Latest Stock Analysis on Urogen Pharma
Urogen Pharma Price Performance
NASDAQ:URGN traded down $0.02 during mid-day trading on Friday, reaching $15.40. 92,005 shares of the company's stock traded hands, compared to its average volume of 1,097,082. The company has a 50 day moving average price of $10.28 and a 200-day moving average price of $10.46. The firm has a market capitalization of $711.25 million, a price-to-earnings ratio of -4.85 and a beta of 1.02. Urogen Pharma has a 12-month low of $3.42 and a 12-month high of $17.00.
Urogen Pharma (NASDAQ:URGN - Get Free Report) last announced its quarterly earnings data on Monday, May 12th. The company reported ($0.92) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.83) by ($0.09). The company had revenue of $20.25 million for the quarter, compared to analysts' expectations of $22.71 million. Urogen Pharma had a negative net margin of 150.68% and a negative return on equity of 97,487.15%. As a group, analysts forecast that Urogen Pharma will post -3.12 EPS for the current year.
Insiders Place Their Bets
In other Urogen Pharma news, insider Mark Schoenberg sold 5,162 shares of the company's stock in a transaction dated Monday, June 9th. The shares were sold at an average price of $7.37, for a total value of $38,043.94. Following the completion of the transaction, the insider owned 153,378 shares in the company, valued at approximately $1,130,395.86. This represents a 3.26% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 5.10% of the company's stock.
About Urogen Pharma
(
Free Report)
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Urogen Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Urogen Pharma wasn't on the list.
While Urogen Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
